发明名称 |
Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
摘要 |
An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). |
申请公布号 |
US9561277(B2) |
申请公布日期 |
2017.02.07 |
申请号 |
US201414502014 |
申请日期 |
2014.09.30 |
申请人 |
SENJU PHARMACEUTICAL CO., LTD. |
发明人 |
Sawa Shirou;Fujita Shuhei |
分类号 |
A01N37/18;A61K31/165;A01N37/44;A61K31/24;A01N37/10;A61K31/19;A61K47/10;A61K9/00;A61K31/196;A61K47/34;A61K47/32;A61K47/02;A61K47/18;A61K47/14 |
主分类号 |
A01N37/18 |
代理机构 |
Wenderoth, Lind & Ponack, L.L.P. |
代理人 |
Wenderoth, Lind & Ponack, L.L.P. |
主权项 |
1. A method for treating an inflammatory disease of an eye, the method comprising administering to said eye a stable aqueous liquid preparation that comprises: (a) a first component; and (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; wherein the hydrate is at least one selected from a 1/2 hydrate, 1hydrate, and 3/2 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation and is present in the preparation at a concentration from about 0.05 w/v % to about 0.2 w/v %; the second component is tyloxapol and is present in said liquid preparation in an amount sufficient to stabilize said first component; wherein said stable liquid preparation is formulated for ophthalmic administration; wherein said liquid preparation is administered to said eye at a dose and a frequency effective to treat said inflammatory disease; and wherein said inflammatory disease is blepharitis, conjunctivitis, scleritis or postoperative inflammation. |
地址 |
Osaka JP |